iRadimed (NASDAQ:IRMD) Updates FY 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.090-2.240 for the period, compared to the consensus estimate of 1.960. The company issued revenue guidance of $91.0 million-$96.0 million, compared to the consensus revenue estimate of $91.2 million. iRadimed also updated its Q3 2026 guidance to 0.540-0.590 EPS.

iRadimed Trading Down 4.6%

NASDAQ IRMD traded down $4.35 on Friday, hitting $90.86. 308,080 shares of the company’s stock were exchanged, compared to its average volume of 111,471. The stock has a 50-day moving average of $94.54 and a 200-day moving average of $95.70. iRadimed has a 52 week low of $57.83 and a 52 week high of $107.90. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, analysts predict that iRadimed will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s payout ratio is currently 43.72%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $120.00.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This represents a 0.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 21,250 shares of company stock worth $1,836,403. Insiders own 34.60% of the company’s stock.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently made changes to their positions in IRMD. Quarry LP acquired a new stake in shares of iRadimed during the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares in the last quarter. Virtus Advisers LLC bought a new position in iRadimed during the third quarter worth $117,000. Aquatic Capital Management LLC grew its holdings in iRadimed by 210,400.0% in the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after purchasing an additional 2,104 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in iRadimed in the third quarter worth $164,000. 92.34% of the stock is currently owned by institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.